Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Results for two new third-generation EGFR TKIs
PFS in recent head-to-head trials: (a) Lux-Lung 7, (b) ARCHER 1050 and... | Download Scientific Diagram
Progression-free survival and overall survival in patients with... | Download Scientific Diagram
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study - The Lancet Regional Health –
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations | SpringerLink
Stream episode ESMO Presidential Symposium: Final overall survival analysis from the FLAURA trial by BMJ talk medicine podcast | Listen online for free on SoundCloud
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | NEJM
EGFR-positive tumors: the issue of optimal therapy across several lines - memoinOncology
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903 - ScienceDirect
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
EGFR-positive tumors: the issue of optimal therapy across several lines - memoinOncology
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
VisualAbstract: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | 2 Minute Medicine
Ο χρήστης Dr. Antonio Calles 🫁🚭 στο Twitter: "Final OS analysis from FLAURA trial. 🤫 Don't tell @EMA_News Exon21 L858R EGFR mutation doesn't show overall survival benefit from osimertinib. #ESMO19 #LCSM https://t.co/Bp5fg54iTt" /
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
